IDEAS home Printed from https://ideas.repec.org/a/spr/snbeco/v3y2023i12d10.1007_s43546-023-00580-8.html
   My bibliography  Save this article

Cost-effectiveness analysis of anti-influenza drugs in adult outpatient settings in Japan

Author

Listed:
  • Naoto Nakagawa

    (Ohu University)

  • Satoru Harada

    (Ohu University)

  • Kiyohito Morita

    (Ohu University)

  • Akimasa Morikawa

    (Pharma Brie)

  • Yukinori Kanazawa

    (Pharma Brie)

  • Leanne Lai

    (Nova Southeastern University)

Abstract

The loss of productivity due to influenza virus (flu) infections (3 to 5 million cases globally), which can sometimes amount to as much as five working days, is a major socioeconomic issue. This study compares baloxavir marboxil’s cost-effectiveness with that of oseltamivir for influenza treatment in adult outpatient settings in Japan from the healthcare-payer perspective. A decision tree model was constructed with probabilities from CAPSTONE 1 for low-risk patients and CAPSTONE 2 for high-risk patients. Direct costs included medical costs and drug prices. Medical costs were obtained from the Japanese Medical fee index (2019 version). Effectiveness outcomes (quality-adjusted life-year [QALY]) were measured using the EQ-5D-5L questionnaire for adult patients who previously experienced flu infection. The time horizon was 14 days. Deterministic and probabilistic sensitivity analyses were performed to examine the robustness of the results. The base case analysis revealed oseltamivir dominated baloxavir marboxil for low-risk patients. However, the incremental cost-effectiveness ratio (ICER) for high-risk patients with body weight

Suggested Citation

  • Naoto Nakagawa & Satoru Harada & Kiyohito Morita & Akimasa Morikawa & Yukinori Kanazawa & Leanne Lai, 2023. "Cost-effectiveness analysis of anti-influenza drugs in adult outpatient settings in Japan," SN Business & Economics, Springer, vol. 3(12), pages 1-16, December.
    • Handle: RePEc:spr:snbeco:v:3:y:2023:i:12:d:10.1007_s43546-023-00580-8
    DOI: 10.1007/s43546-023-00580-8
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s43546-023-00580-8
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s43546-023-00580-8?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Keywords

    Baloxavir marboxil; Influenza virus infection; Cost-effectiveness analysis; QALY; Japan;
    All these keywords.

    JEL classification:

    • I19 - Health, Education, and Welfare - - Health - - - Other

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:snbeco:v:3:y:2023:i:12:d:10.1007_s43546-023-00580-8. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.